Mumbai, May 14 -- Profit before exceptional items and tax climbed 93.26% YoY to Rs 69.65 crore in the quarter ended 31st March 2026. The company reported an exceptional loss of Rs 10.69 crore during the quarter.

EBITDA stood at Rs 108 crore in Q4 FY26, up 71.3% compared with Rs 63 crore posted in Q4 FY25. EBITDA margin improved to 25.4% in Q4 FY26 as against 18.5% in Q4 FY25.

During the quarter, patient volumes grew 11% YoY to 3.5 million, and test volumes increased 14% YoY to 7.6 million, reflecting sustained demand momentum, deeper market penetration and stronger clinician engagement. Revenue per Patient (RPP) improved 11% YoY to Rs 1,210, while Revenue per Test (RPT) increased 8% YoY to Rs 558, supported by favourable mix and higher ...